{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:10Z","timestamp":1791976510593,"version":"4.4.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.atherosclerosis.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T06:50:20Z","timestamp":1530859820000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities"],"prefix":"10.1016","volume":"276","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7238-630X","authenticated-orcid":false,"given":"Jay","family":"Khambhati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Allard-Ratick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik B.","family":"Sandesara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshed A.","family":"Quyyumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Mortality, GBD and Causes of Death, C, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib3","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib4","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.immuni.2013.06.009","article-title":"Immune effector mechanisms implicated in atherosclerosis: from mice to humans","volume":"38","author":"Libby","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib7","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI200319451","article-title":"Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance","volume":"112","author":"Xu","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s001250051162","article-title":"Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation","volume":"42","author":"Schalkwijk","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","article-title":"Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)","volume":"102","author":"Festa","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11883-015-0497-6","article-title":"Atherosclerotic vascular disease in the autoimmune rheumatologic patient","volume":"17","author":"Mankad","year":"2015","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/01.ATV.6.2.131","article-title":"Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque","volume":"6","author":"Jonasson","year":"1986","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib13","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1161\/01.ATV.0000242906.04522.5f","article-title":"Epidemiology complements immunology in the heart","volume":"26","author":"Hansson","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2018.07.007_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1538-7836.2009.03404.x","article-title":"Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)","volume":"7","author":"Ridker","year":"2009","journal-title":"J.\u00a0Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev.pharmtox.48.121806.154841","article-title":"Chemokines and their receptors: drug targets in immunity and inflammation","volume":"48","author":"Viola","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cmet.2012.01.012","article-title":"The ins and outs of inflammatory cells in atheromata","volume":"15","author":"Swirski","year":"2012","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.2205","article-title":"The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques","volume":"13","author":"van Gils","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1056\/NEJMcibr063500","article-title":"The inflammasome\u2013a linebacker of innate defense","volume":"355","author":"Drenth","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib22","doi-asserted-by":"crossref","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajamaki","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.191.2.303","article-title":"Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene","volume":"191","author":"Nicklin","year":"2000","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00005-009-0024-y","article-title":"The role of IL-1 in the pathogenesis of heart disease","volume":"57","author":"Bujak","year":"2009","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib25","first-page":"R229","article-title":"Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6","volume":"269","author":"Guillen","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005344-199401000-00026","article-title":"Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist","volume":"23","author":"Latini","year":"1994","journal-title":"J.\u00a0Cardiovasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacc.2003.07.032","article-title":"Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction","volume":"43","author":"Patti","year":"2004","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib28","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib29","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/circ.105.10.1158","article-title":"Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation","volume":"105","author":"Edfeldt","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib30","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1161\/CIRCULATIONAHA.111.067678","article-title":"Toll-like receptor 7 protects from atherosclerosis by constraining \u201cinflammatory\u201d macrophage activation","volume":"126","author":"Salagianni","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib31","doi-asserted-by":"crossref","first-page":"14008","DOI":"10.3390\/ijms140714008","article-title":"Toll-like receptors in atherosclerosis","volume":"14","author":"Falck-Hansen","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1172\/JCI29950","article-title":"Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata","volume":"117","author":"Swirski","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1172\/JCI28549","article-title":"Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques","volume":"117","author":"Tacke","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1074-7613(03)00174-2","article-title":"Blood monocytes consist of two principal subsets with distinct migratory properties","volume":"19","author":"Geissmann","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib35","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1161\/CIRCULATIONAHA.108.771048","article-title":"P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice","volume":"117","author":"An","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm1601","article-title":"Mast cells promote atherosclerosis by releasing proinflammatory cytokines","volume":"13","author":"Sun","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib37","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.106.660472","article-title":"Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice","volume":"115","author":"Bot","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib38","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/CIRCULATIONAHA.110.961714","article-title":"Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis","volume":"122","author":"Drechsler","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib39","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1161\/CIRCULATIONAHA.105.607333","article-title":"Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events","volume":"113","author":"Healy","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib40","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1172\/JCI27540","article-title":"Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function","volume":"116","author":"Cheng","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.atherosclerosis.2010.12.034","article-title":"Inhibition of IL-17A in atherosclerosis","volume":"215","author":"Cheng","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2011.10.015","article-title":"Circulating angiogenic cell populations, vascular function, and arterial stiffness","volume":"220","author":"Cheng","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib43","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1161\/ATVBAHA.111.228338","article-title":"Interleukin-17 and atherosclerotic vascular disease","volume":"31","author":"Pober","year":"2011","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib44","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.109.924886","article-title":"Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice","volume":"121","author":"Smith","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1172\/JCI200419855","article-title":"Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas","volume":"114","author":"Shimizu","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib46","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1172\/JCI18607","article-title":"Disruption of TGF-beta signaling in T cells accelerates atherosclerosis","volume":"112","author":"Robertson","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm1343","article-title":"Natural regulatory T cells control the development of atherosclerosis in mice","volume":"12","author":"Ait-Oufella","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib48","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI63891","article-title":"Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis","volume":"123","author":"Klingenberg","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1172\/JCI63108","article-title":"Adaptive immunity in atherogenesis: new insights and therapeutic approaches","volume":"123","author":"Lichtman","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib50","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1172\/JCI7272","article-title":"Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice","volume":"109","author":"Caligiuri","year":"2002","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib51","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1084\/jem.20100155","article-title":"B\u00a0cell depletion reduces the development of atherosclerosis in mice","volume":"207","author":"Ait-Oufella","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib52","doi-asserted-by":"crossref","first-page":"e29371","DOI":"10.1371\/journal.pone.0029371","article-title":"Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation","volume":"7","author":"Kyaw","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib53","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/ATVBAHA.111.244731","article-title":"BAFF receptor deficiency reduces the development of atherosclerosis in mice\u2013brief report","volume":"32","author":"Sage","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib54","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1073\/pnas.92.3.821","article-title":"Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis","volume":"92","author":"Palinski","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib55","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib56","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib57","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2014.02.003","article-title":"Clinical evidence of statin therapy in non-dyslipidemic disorders","volume":"88","author":"Ferri","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib59","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A\u00a0test in context: high-sensitivity C-Reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib60","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib61","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.cjca.2017.07.015","article-title":"Association between circulating oxidized LDL and atherosclerotic cardiovascular disease: a meta-analysis of observational studies","volume":"33","author":"Gao","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib62","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s11936-013-0268-z","article-title":"Inflammation and atherosclerosis: disease modulating therapies","volume":"15","author":"Patel","year":"2013","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib63","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib64","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib65","series-title":"ACC News Story","article-title":"CANTOS: new hope for high-risk atherosclerosis patients with severe CKD?","year":"2018"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib66","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes","volume":"71","author":"Everett","year":"2018","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib67","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib68","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib69","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Collaboration","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130709","article-title":"The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: a 12-month longitudinal study in rheumatoid arthritis patients treated with Rituximab, abatacept and tociliziumab","volume":"10","author":"Provan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib71","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib72","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib73","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0008-6363(96)00145-9","article-title":"Synthesis of TNF alpha and TGF beta mRNA in the different micro-environments within atheromatous plaques","volume":"32","author":"Rayment","year":"1996","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib74","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/acr.22166","article-title":"Tumor necrosis factor alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis","volume":"66","author":"Bili","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib76","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib77","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib78","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.amjcard.2010.11.005","article-title":"Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region","volume":"107","author":"Gilbert","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib79","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1248\/bpb.b12-00528","article-title":"A\u00a0novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models","volume":"35","author":"Okamoto","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib80","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/01.CIR.0000049742.68848.99","article-title":"Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes","volume":"107","author":"de Lemos","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.autrev.2009.03.001","article-title":"The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis","volume":"9","author":"van Leeuwen","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib82","doi-asserted-by":"crossref","first-page":"e68039","DOI":"10.1371\/journal.pone.0068039","article-title":"Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice","volume":"8","author":"van Leeuwen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib83","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1179\/1743132813Y.0000000268","article-title":"Anti-oxLDL antibodies are clinically insignificant for stroke patients","volume":"36","author":"Masztalewicz","year":"2014","journal-title":"Neurol. Res."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib84","first-page":"845960","article-title":"Investigation of serum oxidized low-density lipoprotein IgG levels in patients with angiographically defined coronary artery disease","volume":"2014","author":"Moohebati","year":"2014","journal-title":"Int J Vasc Med"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib85","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1542-4758.2012.00683.x","article-title":"Neither oxidized nor anti-oxidized low-density lipoprotein level is associated with atherosclerosis or mortality in hemodialysis patients","volume":"16","author":"Sevinc Ok","year":"2012","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib86","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/ATVBAHA.117.308611","article-title":"ATVB distinguished scientist award: how costimulatory and coinhibitory pathways shape atherosclerosis","volume":"37","author":"Ley","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128523","article-title":"PD-1 and Tim-3 pathways regulate CD8+ T cells function in atherosclerosis","volume":"10","author":"Qiu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib88","first-page":"848","article-title":"Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis","volume":"34","author":"Detert","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib89","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib90","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib91","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ahj.2013.03.018","article-title":"Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis","volume":"166","author":"Everett","year":"2013","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib92","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation","volume":"269","author":"Martinez","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib93","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","article-title":"Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease","volume":"99","author":"Nidorf","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib94","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/heartjnl-2015-308542","article-title":"Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis","volume":"102","author":"Hemkens","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib95","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib96","series-title":"Austrialian New Zealand Clinical Trials Registry","article-title":"The LoDoCo2 Trial: a randomised controlled trial on the effect of low dose Colchicine for secondary prevention of cardiovascular disease in patients with established, stable coronary artery disease","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib97","series-title":"Clinicaltrials.gov","article-title":"Colchicine cardiovascular outcomes trial (COLCOT)","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp038190","article-title":"From asthma to atherosclerosis\u20135-lipoxygenase, leukotrienes, and inflammation","volume":"350","author":"De Caterina","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib99","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2015.02.027","article-title":"A\u00a0phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome","volume":"240","author":"Gaztanaga","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib100","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/jama.293.18.2245","article-title":"Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial","volume":"293","author":"Hakonarson","year":"2005","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib101","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1093\/eurheartj\/ehp311","article-title":"Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability","volume":"30","author":"Munzel","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib102","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI117726","article-title":"Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein","volume":"95","author":"Watson","year":"1995","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib103","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Lp","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib104","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","article-title":"Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque","volume":"118","author":"Serruys","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib105","article-title":"Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease","volume":"5","author":"Wallentin","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib106","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"Investigators","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib107","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib108","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial","volume":"311","author":"Nicholls","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib109","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.atherosclerosis.2006.11.039","article-title":"Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial","volume":"197","author":"Tardif","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib110","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/S0960-894X(02)00516-4","article-title":"Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis","volume":"12","author":"Meng","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.atherosclerosis.2018.07.007_bib111","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(08)60763-1","article-title":"Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial","volume":"371","author":"Tardif","year":"2008","journal-title":"Lancet"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018312036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018312036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T04:04:06Z","timestamp":1561089846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018312036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":111,"alternative-id":["S0021915018312036"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.07.007","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}